CONFERENCE COVERAGE 2015-11-27 Conference Coverage Despite early disappointments, drug developers have bought into immunotherapy for Alzheimer’s disease, banking on a handful of antibodies and active vaccines currently in Phase 2/3 trials and others in Phase 1. As evident from this ...
CONFERENCE COVERAGE 2015-11-27 Conference Coverage It has become a mantra in the Alzheimer’s field that staying active—physically, cognitively, and socially—can protect the brain against decline. But can this be turned into a viable intervention? At the 8th Clinical Trials in Alzheimer ...
Biologische Heilmittel HeelBaden-Baden, Germany
Johns Creek, United States
The Florey Institute of Neuroscience & Mental HealthParkville, Australia
Minneapolis, United States
Union City, United States
Indianapolis, United States
CONFERENCE COVERAGE 2015-11-26 Conference Coverage Geneticists have all but exhausted the genome-wide association approach to finding genetic variants that influence AD risk. Massive meta-analyses of more than 50,000 cases and controls have brought the total number of AD risk genes to ...
PAPER Rabinovich-Toidman P, Rabinovich-Nikitin I, Ezra A, Barbiro B, Fogel H, Slutsky I, Solomon B26600047
PAPER Hwang CJ, Park MH, Choi MK, Choi JS, Oh KW, Hwang DY, Han SB, Hong JT
Acceleration of amyloidogenesis and memory impairment by estrogen deficiency through NF-κB dependent beta-secretase activation in presenilin 2 mutant mice.Brain Behav Immun. 2015 Nov 21; PubMed: 26593275
PAPER Sarlak G, Htoo HH, Hernandez JF, Iizasa H, Checler F, Konietzko U, Song W, Vincent B
Sox2 functionally interacts with βAPP, the βAPP intracellular domain and ADAM10 at a transcriptional level in human cells.Neuroscience. 2015 Nov 17; PubMed: 26592717
PAPER Skogseth RE, Bronnick K, Pereira JB, Mollenhauer B, Weintraub D, Fladby T, Aarsland D
Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.J Parkinsons Dis. 2015 Nov 23; PubMed: 26599300
No filters selected